Skip to main content
Finanzoo GmbH Finanzoo GmbH

ADMA Biologics Value Stock - Dividend - Research Selection

Adma biologics

ISIN: US0008991046 , WKN: A12FAG
Market price date:
Market price:  

Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!

How our site works ...

✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month 
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.


Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet

Description of the company

ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,

NEWS


Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges

2026-03-22
Structure Therapeutics advances oral therapies for diabetes, obesity, and pulmonary disease through its clinical-stage drug pipeline.
Yahoo

Has The Pullback In ADMA Biologics (ADMA) Opened A New Valuation Opportunity?

2026-03-21
For investors wondering whether ADMA Biologics at US$14.32 is a bargain or already pricing in much of the story, this article examines what the current share price may or may not be reflecting. The stock has declined 5.5% over the last 7 days, 12.3% over 30 days, and is down 19.9% year to date, following a very large 3 year return and a gain of around 7x over 5 years. Recent coverage has focused on ADMA Biologics as a biotech name that has already delivered very strong multi year share price...
Yahoo

Novartis Strikes $3B Oncology Deal for Breast Cancer Asset

2026-03-20
NVS bets $2B upfront on SNV4818 to expand precision oncology in breast cancer, targeting a large mutation-driven market and boosting long-term pipeline growth.
Yahoo

PFE Talzenna Combo Shows Strong Efficacy in Wider Prostate Cancer Use

2026-03-20
Pfizer's Talzenna/Xtandi combo meets phase III goals, significantly delaying disease progression in HRR-mutated metastatic castration-sensitive prostate cancer patients.
Yahoo

FDA Approves Novo Nordisk's Higher-Dose Wegovy for Obesity Patients

2026-03-20
NVO wins FDA's accelerated nod for a higher 7.2 mg Wegovy dose, backed by strong phase III weight-loss data, with a U.S. launch planned for April 2026.
Yahoo

Adma Biologics (ADMA) Advances While Market Declines: Some Information for Investors

2026-03-19
In the closing of the recent trading day, Adma Biologics (ADMA) stood at $15.02, denoting a +1.01% move from the preceding trading day.
Yahoo

Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?

2026-03-19
Based on the average brokerage recommendation (ABR), Adma Biologics (ADMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Yahoo

ALDX Crashes 71% as FDA Issues Third CRL for Dry Eye Disease Drug NDA

2026-03-18
Aldeyra Therapeutics stock plunges 71% after the FDA issues a third CRL for the resubmitted reproxalap NDA for the treatment of dry eye disease.
Yahoo

Zacks Industry Outlook Highlights Terns Pharmaceuticals, ADMA Biologics, ANI Pharmaceuticals and Liquidia

2026-03-16
Biotech momentum in 2026 spotlights companies like Liquidia and ANI Pharmaceuticals as pipeline innovation, drug demand and rising M&A activity drive sector interest.
Yahoo

A Look At ADMA Biologics (ADMA) Valuation After Recent Share Price Swings

2026-03-15
Recent performance snapshot and context ADMA Biologics (ADMA) has attracted fresh attention after a mixed stretch in the share price, with gains of about 1% over the past day contrasting with weaker moves over the past month and past 3 months. For investors, that split in recent returns often raises a practical question: whether the current price is starting to reflect company fundamentals like revenue, profitability and overall business momentum, or if sentiment is still the main driver...
Yahoo